Sign up for news updates

Industry Connections

VIEW MORE

Industry Connections

VIEW MORE

Sponsored Content
This information is being distributed by the American Diabetes Association® (ADA) as a sponsor benefit. Reference to commercial products, processes, or services by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the ADA. The views and opinions of sponsors expressed herein do not necessarily state or reflect those of the ADA, and shall not be used for advertising or product endorsement purposes.

Discover the Omnipod® 5 Advantage at ADA Scientific Sessions

With its powerful algorithm in every Pod, the Omnipod 5 Automated Insulin Delivery (AID) System delivers improved glycemic results,1-3 a tube-free lifestyle, and the features patients want – all in a waterproof system that users agree is easy to use.*,4

Omnipod 5 real-world evidence demonstrated that type 1 and type 2 patients achieved over 80% time in range (TIR) with optimized settings.5 Find out how and discover the advantages of Omnipod 5, the #1 patient-requested and #1 prescribed AID system in the U.S.6,7

5. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014

From Standards to Success: Bridging the Gap with Omnipod 5

ADA Standards state AID is now the preferred insulin delivery method (over MDI, continuous subcutaneous insulin infusion and sensor-augmented pumps).8

Help your type 1 diabetes patients over the age of 2 years, and adults 18+ with type 2 diabetes transition to the Omnipod 5 AID System for simplified diabetes management, outstanding clinical results, and accessible coverage available through the pharmacy. Over 90% insured patients nationwide are covered for Omnipod 5.9

Clinical Results Across T1D and T2D

Switching to Omnipod 5 From MDI Boosts TIR for T1D Patients

– The RADIANT Randomized Controlled Trial showed improved TIR by an average of 23% for T1D adults and 20% for children and adolescents with T1D, compared with MDI users10

Improved Results for People with T2 Diabetes on Omnipod 5

– The SECURE T2D study showed a 2.1% decrease in A1C for people living with type 2 diabetes with a baseline A1C ≥9%, without increasing hypoglycemia3

Strong Results Start with Strong Settings

53% of Omnipod 5 users not achieving glycemic targets do not frequently use the lowest Target Glucose setting of 110 mg/dL.11 Get real-world insights and the optimized settings to maximize TIR for your Omnipod 5 patients.

See what’s next for Omnipod at Booth #1918

Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see omnipod.com/safety for important safety information.

*The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.

**Only available for users with valid prescription and coverage through their pharmacy benefit. Exact coverage depends on patient’s insurance plan. Upgrades subject to user’s insurance coverage.

  1. Brown S, et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6-70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time 70-180 mg/dL as measured by CGM in adults/adolescents and children, ST vs. 3-month Omnipod 5: 64.7% vs. 73.9%; 52.5% vs. 68.0%, P<0.0001, respectively.
  2. Sherr JL, et al. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2-5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (70-180mg/dL) in very young children (2-5.9 yrs) as measured by CGM: ST = 57.2%, 3-month Omnipod 5 = 68.1%, P<0.05.
  3. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time in range (70-180 mg/dL): ST vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001. Mean time <70 mg/dL as measured by CGM: ST = 0.2%, 3-month Omnipod 5 = 0.2%. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%).
  4. Insulet Data on File. OP5-003 Clinical Study Report. 2024.13-week randomized, parallel-group clinical trial conducted among 194 adults (age 18-70) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 System versus pump therapy with CGM.
  5. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014
  6. 2025, Data on file
  7. Omnipod was the pump most frequently requested by people with type 1 and type 2 diabetes in a survey with Endocrinologists conducted by dQ&A across the United States. n=77 (T1) and n=63 (T2); H2 2024; P.25.
  8. American Diabetes Association Professional Practice Committee for Diabetes. 7. Diabetes technology: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl. 1): S150–S165
  9. Reflects coverage for Omnipod 5 DexG7G6 Intro Kit and Omnipod 5 DexG7G6 Pods in commercial channel only. Majority defined as >50%. Source: Managed Markets Insights & Technology, LLC. Data as of April 2025.
  10. Wilmot E, et al. Lancet (2026) A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. TBR (<70 mg/dL) at 13-weeks: non-inferiority was met with 2.56% TBR with Omnipod 5. Data on File. 2025. RF-042025-00020 & RF-052025-00033
  11. Insulet data on file. 2025. Retrospective analysis including 103,369 T1D users with TIR (3.9-10.0 mmol/L or 70-180 mg/dL) <70%. 54,365 (53%) did not use the 110mg/dL (6.1mmol/L) target as their average glucose target setting. RF-062025-00038

©2026 Insulet Corporation. Omnipod, SmartAdjust, and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved.

Learn More